Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

E F Magavern, J C Kaski, R M Turner, H Drexel, A Janmohamed, A Scourfield, D Burrage, C N Floyd, E Adeyeye, J Tamargo, B S Lewis, Keld Per Kjeldsen, A Niessner, S Wassmann, P Sulzgruber, P Borry, S Agewall, A G Semb, G Savarese, M PirmohamedM J Caulfield

4 Citations (Scopus)

Abstract

Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

Original languageEnglish
Article numberpvab063
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Volume8
Issue number1
Pages (from-to)100-103
Number of pages4
ISSN2055-6837
DOIs
Publication statusPublished - 5 Jan 2022

Keywords

  • Genetics
  • Pharmacogenomics
  • Pharmacotherapy
  • Therapeutics

Fingerprint

Dive into the research topics of 'Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy'. Together they form a unique fingerprint.

Cite this